Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07CWD
|
||||
| Former ID |
DAP000739
|
||||
| Drug Name |
Hydroxyurea
|
||||
| Synonyms |
Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
CH4N2O2
|
||||
| InChI |
InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
|
||||
| InChIKey |
VSNHCAURESNICA-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 127-07-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9256, 90752, 601956, 842099, 3135371, 5137976, 7847407, 7849615, 7979551, 8136972, 8149381, 8152311, 11111283, 11120331, 11120819, 11121307, 11335731, 11360970, 11363803, 11366365, 11368927, 11371484, 11373522, 11377089, 11404371, 11407166, 11446788, 11461942, 11483983, 11487880, 11490278, 11491827, 11494723, 11538819, 12014598, 14747331, 17137218, 17405158, 24278474, 24879294, 26611777, 26679201, 26697171, 26747533, 26747534, 26747535, 26758911, 29222781, 30388908, 32810068
|
||||
| ChEBI ID |
ChEBI:44423
|
||||
| SuperDrug ATC ID |
L01XX05
|
||||
| SuperDrug CAS ID |
cas=000127071
|
||||
| Target and Pathway | |||||
| Target(s) | Ribonucleoside-diphosphatereductase subunit M2 | Target Info | Modulator | [556264] | |
| BioCyc Pathway | Pyrimidine deoxyribonucleotides biosynthesis from CTP | ||||
| Pyrimidine deoxyribonucleotides de novo biosynthesis | |||||
| Guanosine nucleotides de novo biosynthesis | |||||
| Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis | |||||
| Superpathway of purine nucleotide salvage | |||||
| Purine nucleotides de novo biosynthesis | |||||
| Adenosine deoxyribonucleotides de novo biosynthesis | |||||
| Guanosine deoxyribonucleotides de novo biosynthesis | |||||
| NetPath Pathway | EGFR1 Signaling Pathway | ||||
| Pathway Interaction Database | E2F transcription factor network | ||||
| PathWhiz Pathway | Purine Metabolism | ||||
| Pyrimidine Metabolism | |||||
| References | |||||
| Ref 537415 | Guidelines of care for the management of psoriasis and psoriatic arthritis Section . Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Jun 1. | ||||
| Ref 541904 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6822). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.